Phase II trial of biweekly carboplatin and nab-paclitaxel with concurrent radiotherapy for patients with locally advanced unresectable stage III non-small cell lung cancer
| العنوان: | Phase II trial of biweekly carboplatin and nab-paclitaxel with concurrent radiotherapy for patients with locally advanced unresectable stage III non-small cell lung cancer |
|---|---|
| المؤلفون: | Shingo Takanashi, Masamichi Itoga, Junichi Yokouchi, Yoshiko Ishioka, Fumihiko Okumura, Masahiko Aoki, Yukihiro Hasegawa, Chiori Tabe, Kageaki Taima, Hisashi Tanaka, Sadatomo Tasaka |
| المصدر: | Journal of Clinical Oncology. 38:e21078-e21078 |
| بيانات النشر: | American Society of Clinical Oncology (ASCO), 2020. |
| سنة النشر: | 2020 |
| مصطلحات موضوعية: | Oncology, Cancer Research, medicine.medical_specialty, Lung, business.industry, medicine.medical_treatment, Standard treatment, Cell, Locally advanced, Carboplatin, Stage III Non-Small Cell Lung Cancer, Radiation therapy, chemistry.chemical_compound, medicine.anatomical_structure, chemistry, Internal medicine, medicine, business, Nab-paclitaxel |
| الوصف: | e21078 Background: Concurrent chemoradiotherapy (CCRT) is the standard treatment for patients with locally advanced non-small cell lung cell cancer (LA-NSCLC). We previously reported the phase I study of biweekly carboplatin and nab-paclitaxel (nab-PTX) with RT. Recommended dose for phase II study was carboplatin (AUC 4) and nab-PTX (100 mg/m2) (J Clin Oncol 2015 suppl; abstr 7529). Here we report the phase II part designed to assess the efficacy of biweekly carboplatin and nab-PTX with concurrent RT (UMIN000023802). Methods: Patients with inoperable stage Ⅲ NSCLC were treated with carboplatin (AUC 4) and nab-PTX 100 mg/m2 on days 1, 15, and 29. Thoracic radiotherapy was administered from day 1 to a total dose of 60 Gy in 30 fractions. Consolidation chemotherapy after CCRT was 2 cycles of carboplatin (AUC 6) on day 1 and nab-PTX 100 mg/m2 on days 1, 8, and 15. The primary endpoint for the phase II part is 2-year overall survival (OS) rate. Assuming an expected survival rate was 60% and a lower limit was 35% (alfa 0.05, beta 0.2). Secondary endpoints were the objective response rate (ORR), progression-free survival (PFS), OS, and safety profile. Results: A total of 28 patients (median age 66 years, male 94%) were enrolled. Of the evaluable patients (n = 28), the rate of 2-year OS was 67.8% (95% CI: 49.3–82.1). The ORR was 96%, a median follow-up time was 33.2 months. Median PFS was 18.2 months (95% CI 13.1–not reached), and median OS was not reached (95% CI, 25.6–not reached). The most common toxicities of grade 3 or higher were neutropenia (60.5%), anemia (14.2%), thrombocytopenia (7.6%) and pneumonitis (3.6%). Conclusions: This study achieved the primary endpoint. Biweekly carboplatin and nab-PTX with concurrent RT therapy was well tolerated and promising systemic antitumor activity for patients with LA-NSCLC. Clinical trial information: 000023802 . |
| تدمد: | 1527-7755 0732-183X 0000-2380 |
| DOI: | 10.1200/jco.2020.38.15_suppl.e21078 |
| URL الوصول: | https://explore.openaire.eu/search/publication?articleId=doi_________::7afaa62192aeff89908261a8bdf70393 https://doi.org/10.1200/jco.2020.38.15_suppl.e21078 |
| رقم الانضمام: | edsair.doi...........7afaa62192aeff89908261a8bdf70393 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 15277755 0732183X 00002380 |
|---|---|
| DOI: | 10.1200/jco.2020.38.15_suppl.e21078 |